1
|
Irizarry AR, Yan G, Zeng Q, Lucchesi J, Hamang MJ, Ma YL, Rong JX. Defective enamel and bone development in sodium-dependent citrate transporter (NaCT) Slc13a5 deficient mice. PLoS One 2017; 12:e0175465. [PMID: 28406943 PMCID: PMC5391028 DOI: 10.1371/journal.pone.0175465] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2016] [Accepted: 03/27/2017] [Indexed: 01/08/2023] Open
Abstract
There has been growing recognition of the essential roles of citrate in biomechanical properties of mineralized tissues, including teeth and bone. However, the sources of citrate in these tissues have not been well defined, and the contribution of citrate to the regulation of odontogenesis and osteogenesis has not been examined. Here, tooth and bone phenotypes were examined in sodium-dependent citrate transporter (NaCT) Slc13a5 deficient C57BL/6 mice at 13 and 32 weeks of age. Slc13a5 deficiency led to defective tooth development, characterized by absence of mature enamel, formation of aberrant enamel matrix, and dysplasia and hyperplasia of the enamel organ epithelium that progressed with age. These abnormalities were associated with fragile teeth with a possible predisposition to tooth abscesses. The lack of mature enamel was consistent with amelogenesis imperfecta. Furthermore, Slc13a5 deficiency led to decreased bone mineral density and impaired bone formation in 13-week-old mice but not in older mice. The findings revealed the potentially important role of citrate and Slc13a5 in the development and function of teeth and bone.
Collapse
Affiliation(s)
- Armando R. Irizarry
- Department of Pathology, Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, IN, United States of America
- * E-mail: (JXR); (ARI)
| | - Guirui Yan
- Lilly China R&D Center, Eli Lilly & Company, Building 8, No. 338, Zhangjiang Hi-Tech Park, Shanghai, People’s Republic of China
| | - Qingqiang Zeng
- Musculoskeletal Research, Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, IN, United States of America
| | - Jonathan Lucchesi
- Musculoskeletal Research, Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, IN, United States of America
| | - Matthew J. Hamang
- Musculoskeletal Research, Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, IN, United States of America
| | - Yanfei L. Ma
- Musculoskeletal Research, Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, IN, United States of America
| | - James Xiaojun Rong
- Lilly China R&D Center, Eli Lilly & Company, Building 8, No. 338, Zhangjiang Hi-Tech Park, Shanghai, People’s Republic of China
- * E-mail: (JXR); (ARI)
| |
Collapse
|
2
|
Okragly AJ, Hamang MJ, Pena EA, Baker HE, Bullock HA, Lucchesi J, Martin AP, Ma YL, Benschop RJ. Elevated levels of Interleukin (IL)-33 induce bone pathology but absence of IL-33 does not negatively impact normal bone homeostasis. Cytokine 2016; 79:66-73. [PMID: 26771472 DOI: 10.1016/j.cyto.2015.12.011] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2015] [Revised: 12/05/2015] [Accepted: 12/11/2015] [Indexed: 10/22/2022]
Abstract
Interleukin (IL)-33 is a member of the IL-1 family. IL-33 effects are mediated through its receptor, ST2 and IL-1RAcP, and its signaling induces the production of a number of pro-inflammatory mediators, including TNFα, IL-1β, IL-6, and IFN-γ. There are conflicting reports on the role of IL-33 in bone homeostasis, with some demonstrating a bone protective role for IL-33 whilst others show that IL-33 induces inflammatory arthritis with concurrent bone destruction. To better clarify the role IL-33 plays in bone biology in vivo, we studied IL-33 KO mice as well as mice in which the cytokine form of IL-33 was overexpressed. Mid-femur cortical bone mineral density (BMD) and bone strength were similar in the IL-33 KO mice compared to WT animals during the first 8months of life. However, in the absence of IL-33, we observed higher BMD in lumbar vertebrae and distal femur in female mice. In contrast, overexpression of IL-33 resulted in a marked and rapid reduction of bone volume, mineral density and strength. Moreover, this was associated with a robust increase in inflammatory cytokines (including IL-6 and IFN-γ), suggesting the bone pathology could be a direct effect of IL-33 or an indirect effect due to the induction of other mediators. Furthermore, the detrimental bone effects were accompanied by increases in osteoclast number and the bone resorption marker of C-terminal telopeptide collagen-I (CTX-I). Together, these results demonstrate that absence of IL-33 has no negative consequences in normal bone homeostasis while high levels of circulating IL-33 contributes to pathological bone loss.
Collapse
Affiliation(s)
- Angela J Okragly
- Biotechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - Matthew J Hamang
- Musculoskeletal-Biology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - Emily A Pena
- Musculoskeletal-Biology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - Hana E Baker
- Biotechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - Heather A Bullock
- Musculoskeletal-Biology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - Jonathan Lucchesi
- Musculoskeletal-Biology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - Andrea P Martin
- Biotechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - Y Linda Ma
- Musculoskeletal-Biology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
| | - Robert J Benschop
- Biotechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.
| |
Collapse
|